Korro Bio, Inc. Retained Earnings
Korro Bio, Inc. (KRRO) had Retained Earnings of -$422.39 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-06
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$422.39M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$403.47M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$383.85M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$333.80M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$422.39M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | -$403.47M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | -$383.85M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | -$333.80M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | -$315.74M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | -$289.97M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | -$266.59M 10-K · filed 2026-03-12 | |
| 2024-09-30 | -$245.39M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | -$224.39M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | -$202.56M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | -$183.00M 10-K · filed 2025-03-18 | |
| 2023-09-30 | -$303.62M 10-Q · filed 2023-11-02 | |
| 2023-06-30 | -$292.00M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | -$281.21M 10-Q · filed 2023-05-12 | |
| 2022-12-31 | -$101.83M 10-K · filed 2024-03-26 | -$261.67M 10-K · filed 2023-03-10 |
| 2022-09-30 | -$244.30M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | -$224.76M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | -$203.47M 10-Q · filed 2022-05-04 | |
| 2021-12-31 | -$180.09M 10-K · filed 2023-03-10 | |
| 2021-09-30 | -$158.59M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | -$133.43M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | -$115.77M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | -$95.40M 10-K · filed 2022-03-15 | |
| 2020-09-30 | -$85.17M 10-Q · filed 2020-11-16 | |
| 2020-06-30 | -$79.83M 10-Q · filed 2020-08-12 | |
| 2020-03-31 | -$73.80M 10-Q · filed 2020-05-14 | |
| 2019-12-31 | -$68.89M 10-K · filed 2021-03-29 | |
| 2019-09-30 | -$63.35M 10-Q · filed 2019-11-18 | |
| 2018-12-31 | -$49.09M 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |